Peter Pellerito, CEO, MediLynx
For doctors to make informed decisions about a patient’s medical condition, it is pivotal that they be equipped with the appropriate tools and have access to all of the important information—immediately and accurately. Time is of the essence when it comes to diagnosis. Today, the cardiovascular space is awash with numerous remote monitoring service providers that offer solutions to continuously monitor, collect, and analyze patient health data. A leader among them is Plano, TX-based MediLynx, a leading cardiac monitoring service provider that delivers superior diagnostics solutions and support services to help clinicians provide patients the best possible care. Spearheaded by Peter Pellerito, an accomplished visionary and industry veteran, the firm’s flagship products, MediLynx Arrhythmia Diagnostics Platform and PocketECG®, offer physicians a new level of confidence when it comes to determining a patient’s next steps in care. “The hallmark of our branding is the clinical efficacy of our reports and 24x7 support that we offer to both clinicians and patients. Our highly-trained technicians and customer care specialists work round-the-clock to provide continuous monitoring, reporting, training, and support for cardiology practices and their patients,” says Pellerito, CEO of MediLynx.
Leading from the Front
Many existing telemetry systems fail to provide physicians all the necessary information about a patient’s heartbeat to determine the cause of the arrhythmia. They only give snapshots of time or fail to transmit the onset or offset of every arrhythmia. MediLynx delivers True Full Disclosure™ through its advanced Arrhythmia Diagnostics Platform and gives physicians complete and accurate visibility into patients’ heart health in the form of streamlined, detailed reports. “This continuous, full-disclosure online monitoring provides distinct advantages over other monitoring methods such as the 24- or 48-hour Holter and patch—high-quality analysis and the ability to easily extend monitoring duration to ensure an accurate diagnosis,” mentions Pellerito. These reports deliver the data physicians need to make the best clinical decisions to elevate patients’ standard of care. What’s more? MediLynx provides clinicians access to all the data they need—from the most in-depth reporting to concise summaries—in simple formats.
Enabling Real-Time Decision-Making
PocketECG is MediLynx’s integrated arrhythmia diagnostic system, which combines Holter, event monitoring, and advanced mobile cardiac telemetry in one smartphone-sized device, allowing physicians to monitor a patient’s heart rhythm, rate, and symptoms remotely. The wearable device is engineered to provide clinicians with continuous full-disclosure ECG signals, enabling powerful diagnostics, sophisticated analysis, and real-time decision-making.
The hallmark of our branding is the clinical efficacy of our reports and 24x7 support that we offer to both clinicians and patients
Further discussing its benefits, Pellerito explains, “Our certified ECG technicians monitor the device through our global virtual servers. They can easily identify arrhythmia and other heart-rhythm related issues and account for every beat occurring during a session. PocketECG captures, classifies, and transmits heartbeat in near real time to our monitoring network, where deep learning algorithms are used for accurate detection of abnormalities and arrhythmia.”
Setting New Diagnostic Standards
According to the CEO, what truly sets PocketECG apart from other monitoring solutions is its ability to offer physicians End of Study (EOS) reports for interpretation within 24-48 hours of a patient’s session. Traditional Holter devices typically provide reports to physicians only two to three weeks after a patient’s visit. Another notable aspect of PocketECG is that clinicians have four monitoring options in a single, integrated system. “The system can easily switch between Holter, Extended Holter, Event, and Telemetry modes without requiring patients to visit the physician’s office or switch devices,” adds Pellerito. The transmission of PocketECG’s full-disclosure signal for up to 30 days enables MediLynx’s proprietary neural networks to efficiently perform analysis and reporting—offering the industry’s highest diagnostic yield for better patient diagnosis and treatment. “In short, full-disclosure, sensitivity and specificity with the algorithms, and the ability to produce clinically efficient reports with a high level of sensitivity are huge components of what we provide to our customers,” he states.
Another differentiating factor is MediLynx’s 24x7 in-house customer support service. “When our customers receive the electrophysiology monitoring device, we offer them real-time assistance with using the device, including setup, operation, and other device-related issues,” states Pellerito. In fact, MediLynx’s holistic approach to cardiac monitoring has been a boon to physicians and patients alike during the COVID-19 pandemic. The organization also provides patients with insurance and billing services. Patients can then pay the required amount online via MediLynx’s self-service portal or use the firm’s patient-friendly payment programs and need-based financial assistance.
Elevating the Standard of Care
Since its inception in 2013, MediLynx has been customer-centric and patient-oriented. More recently, in addition to offering its services for hospitals and private practices, the firm has expanded its ship-to-home services and telemedicine capability, making it easy for physicians and nurse practitioners to gather real-time information on a patient’s health. With global reach, MediLynx is currently involved in patient monitoring across 12 different countries and participates in several research activities. As a part of its plan for the future, the company is developing wearables and patches, along with enhancing its products’ AI and neural networks. “We’re actively involved in the development of other clinical products in cardiology and have been chosen by large clinical organizations for research. We are actively investing in globalization, product development, and CRO research. MediLynx will continue to expand on these initiatives to ensure better efficiency for clients,” wraps up Pellerito.